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AIT: Allergen-specific immunotherapyIn the past, the development of more effective, safe, convenient,
broadly applicable, and easy to manufacture vaccines for
allergen-specific immunotherapy (AIT) has been limited by the
poor quality of natural allergen extracts. Progress made in the
field of molecular allergen characterization has now made it
possible to produce defined vaccines for AIT and eventually for
preventive allergy vaccination based on recombinant DNA
technology and synthetic peptide chemistry. Here we review the
characteristics of recombinant and synthetic allergy vaccines that
have reached clinical evaluation and discuss how molecular
vaccine approaches can make AIT more safe and effective and
thus more convenient. Furthermore, we discuss how new
technologies can facilitate the reproducible manufacturing of
vaccines of pharmaceutical grade for inhalant, food, and venom
allergens. Allergy vaccines in clinical trials based on recombinant
allergens, recombinant allergen derivatives, and synthetic
peptides allow us to target selectively different immune
mechanisms, and certain of those show features that might make
them applicable not only for therapeutic but also for prophylactic
vaccination. (J Allergy Clin Immunol 2016;137:351-7.)
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Allergen-specific immunotherapy (AIT) was reported first by
Leonard Noon in 1911.1 Noon injected grass pollen extract into
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http://dx.doi.org/10.1016/j.jaci.2015.12.1299observed clinical improvement for almost 1 year in the treated
patients. In his article Noon quotes earlier work by William
Dunbar,2 who had shown that anti-sera raised against pollen
allergen extract could neutralize allergen-induced conjunctival
inflammation. The early work of Dunbar had already indicated
that a major effect of AIT was caused by induction of allergen-
specific blocking antibodies. In 1935, more than 40 years before
the identification of IgE antibodies, Cooke et al3 reported a series
of elegant experiments showing that allergen-specific IgG
antibodies induced by AIT can suppress allergen-induced skin
inflammation. Since then, the importance of allergen-specific
IgG antibodies that compete with IgE for binding to the allergens
has been demonstrated by numerous studies as a major
mechanism of the mode of action of AIT,4 and therefore one
might consider AIT and in particular the traditional form of
subcutaneous AIT as a therapeutic vaccine.5
There are several important features that suggest that AIT has
many advantages over symptomatic treatment with anti-
inflammatory drugs and biologics when applied as recommended
according to guidelines.6 First of all, AIT functions in an allergen-
specific and thus causative manner as a therapeutic vaccine. It
uses the immune system of the patient to establish a counterim-
mune response, antagonizing the allergic immune response by
vaccination with the disease-causing allergens or derivatives
thereof. Therefore, as with other vaccines, allergy vaccines can
be relatively easily produced, and the costs of AIT are low, in
particular when compared with those of treatment with biologic
agents, such as anti-cytokine antibodies.7 Unlike anti-
inflammatory treatment, AIT can stop the progression of mild
forms (ie, rhinitis) of allergy toward severe forms (ie, asthma)
and thus modifies the natural course of disease.8,9 Furthermore,
AIT has long-lasting effects, even after discontinuation of treat-
ment, which cannot be achieved with symptomatic treatment.10
The achievement of long-term ‘‘clinical tolerance’’ can be
achieved through induction of long-lived B cells or plasma cells
secreting high-affinity antibodies11 and/or through a reduction
in boosts of allergen-specific IgE, which occurs after natural
allergen contact.12-14
Diagnosis of the disease-causing allergens and monitoring of
treatment have been greatly facilitated through the availability of
molecular allergy diagnosis, also termed component-resolved351
FIG 1. Requirements for improved allergy vaccines.
FIG 2. Steps toward improvement of allergy vaccines.
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cules allow detection of IgE reactivities and treatment-induced
IgG antibody responses toward a comprehensive set of aller-
gens.16 Thus tools are available for more precise prescription of
allergy vaccines and for controlling the effects of the vaccine.16,19
However, there are several important bottlenecks (Fig 1) that
limit the broad applicability of AIT for allergy treatment. In
this review we will discuss how these bottlenecks have been ad-
dressed in the past with traditional technologies and how modern
technologies of molecular treatment might lead to a breakthrough
of AIT not only for global allergy treatment but also ultimately for
allergy prevention.AREAS OF AIT THAT NEED IMPROVEMENT
Fig 1 provides an overview of areas in which improvement of
AIT is needed. Some of these areas (safety, efficacy, and conve-
nience) are closely connected to each other. A major problem in
AIT is that administration of allergens can induce side effects in
patients, which, in the worst-case scenario, can lead to
anaphylactic shock and death.20 Side effects can be classified as
immediate side effects, which are caused by allergen-induced
cross-linking of mast cell– and basophil-bound IgE antibodies.
These side effects occur within 30 minutes after administration
of the vaccine and, when induced systemically, can give rise to
life-threatening anaphylactic shock. Systemic activation of mast
cells and basophils occurs mainly when relevant doses of
IgE-reactive allergens are distributed systemically in the body.
A reduction in the risk of immediate systemic side effects can
be achieved by keeping allergens locally bound at the application
site, such as through the use of certain adjuvants, such as
aluminum hydroxide, which has been introduced already in
1935 and led to a profound reduction of severe systemic side
effects (Fig 2).21 Another way to reduce side effects has been
reduction of the IgE reactivity of allergen extracts, which in the
past has been achieved by chemical modification, such as denatur-
ation with aldehydes.22 Such modified allergen extracts thatexhibit reduced IgE reactivity are termed ‘‘allergoids’’ (Fig 2).
Interestingly, even strong reduction of IgE reactivity cannot
eliminate side effects because late-phase side effects can occur
even in the absence of IgE reactivity caused by the presence of un-
destroyed T-cell epitopes. In a classical study it has been shown
that even non–IgE-reactive T-cell epitope–containing allergen
peptides can induce systemic late-phase side effects that occur af-
ter hours and are caused by IgE-independent activation of
allergen-specific T cells.23 Late-phase side effects have been
also reported for AITwith allergoids made from natural allergen
extracts.24,25 Because the IgE reactivity of allergoids is usually
strongly reduced, these late-phase side effects can be also
mediated by activation of allergen-specific T cells because
allergoids retain their ability to stimulate T cells.26
Another possibility to reduce the risk of side effects is to begin
treatment with very low doses and to continuously increase the
dose until a therapeutically effective maintenance dose has been
reached. As a result of the need for updosing, AIT requires
multiple administrations, whichmake the treatment inconvenient.
Therefore alternative routes of administration, such as sublingual,
oral, and epicutaneous application, were developed, but these
treatments also require frequent administration and are
inconvenient.27-30 For example, sublingual treatment requires
daily administration, and therefore it is not surprising that the
compliance of patients receiving AIT is low and particularly
low for sublingual AIT.31
Another area of AIT in which improvement is needed is clinical
efficacy. Very often it is not possible to reach and maintain the
therapeutically active dose in patients because of side effects.
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widely varying potency in different quantities. Several studies
have shown that natural allergen extracts from different
manufacturers contain widely varying contents of allergens and
that often important allergens are lacking.32-34 It is also known
that individual allergens possess varying immunogenicity (ie,
ability to induce IgG responses). For example, certain grass pollen
allergens induce high IgG responses (eg, Phl p 5), whereas others
induce only low or no IgG responses (eg, Phl p 2 and Phl p
1).12,35,36 Accordingly, allergen extract–based forms of AIT can
induce only partial protection. This brings us to the major
bottleneck for the further development of AIT, which is related
to the use of natural allergen extracts as a source for
manufacturing the vaccines. The huge variations regarding
amounts, potencies, and immunogenicity of individual allergen
molecules in natural allergen extracts cannot be controlled or
even manipulated by pharmaceutical production processes.
Also, modern technologies, such as proteomics tools or mass
spectrometry, do not allow the adequate quantification of
immunogenic allergens or allergen derivatives in extracts.34
Therefore one cannot expect any further substantial improvement
of AIT based on traditional allergen extract–based forms of
treatment.37 Requirements for innovative forms of AIT are
summarized in Fig 1 and include high safety. The vaccine should
have no anaphylactic potential and induce as few systemic
late-phase side effects as possible. AIT vaccines should be
effective and induce suppression of clinical symptoms early after
the start of the treatment and should have sustained effects, even
after discontinuation of the treatment. It should be possible to
achieve the therapeutic effect with few doses of application to
increase patient compliance. Manufacturing of the vaccine must
be reproducible and follow the pharmaceutical requirements set
for vaccines and should be possible at low costs. The technology
used for the production of the vaccine and the resulting vaccines
should be applicable for all allergen sources, including
respiratory, food, and venom allergens.
Finally and importantly, it has become clear that one of the big
advantages of AIT is that it can prevent the progression of mild to
severe forms of allergy. It has been shown that AIT can prevent the
progression of rhinitis to asthmawhengiven in children.8,9 Through
analysis of the evolution of IgE responses in early childhood with
microarrayed allergen molecules in birth cohorts, it seems to
become possible to predict the transition of silent and
asymptomatic IgE sensitization toward the development of allergic
symptoms.38-41 Accordingly, one might consider applying AIT
already to children who are sensitized but do not yet have
symptoms to prevent the development of allergic symptoms or
even as early intervention to prevent the development of allergic
sensitization.42 In fact, we are beginning to see the first studies
that make an attempt toward prophylactic AIT.43-45 However, it
will be necessary to have innovative AIT technologies that
selectively induce protective IgG responses and/or tolerance
without inducing and/or boosting IgE responses for preventiveAIT.HOW MOLECULAR APPROACHES CAN
CONTRIBUTE TO IMPROVEMENT OF AIT
In this article we focus on defined molecular approaches for
improvement of specific immunotherapy, which are based on
purified recombinant allergens, recombinant allergen derivatives,
and allergen-derived peptides. Problems associated with the badquality of natural allergen extracts can be overcome by the use of
purified recombinant allergen molecules, which can be produced
in reproducible quality according to pharmaceutical require-
ments. Fusion of several allergens or of hypoallergenic allergen
derivatives in the form of hybrid molecules allows for combining
several allergens within one molecule and increasing the
immunogenicity of the individual components.35,46
In a classical study Pauli et al47 have demonstrated that rBet v 1
was equally effective as birch pollen extract for subcutaneousAIT
of patients with birch pollen allergy. However, rBet v 1 retains the
allergenic properties of nBet v 1, and therefore patients had to be
treated with a rather inconvenient updosing schedule andmonthly
maintenance injections in this trial. To increase the safety of AIT
based on rBet v 1, tablet formulations of rBet v 1 for sublingual
treatment are currently being developed that use pharmaceutical
grade recombinant allergen,48 but sublingual treatment will
require multiple administrations and therefore remains an
inconvenient form of treatment. It is also possible that sublingual
application of rBet v 1 will induce oral allergy syndrome as a
possible side effect. Finally, SLITwith rBet v 1 can strongly boost
allergen-specific IgE production, as was observed for grass pollen
allergen extract–containing tablets.30
Currently available data for recombinant birch pollen and
recombinant grass pollen allergens thus suggest that recombinant
allergens can replace natural allergen extracts.47,49,50 They offer
the advantage of being pharmaceutically well-defined allergens
that can be easily produced, but side effects will remain similar
as for natural allergen extracts. In addition, it will not be possible
to reduce the numbers of treatments, and treatment will remain as
inconvenient as for allergen extracts. Furthermore, recombinant
wild-type allergens boost allergen-specific IgE production and
therefore might not be suitable for preventive vaccination.
One possibility to reduce side effects is the genetic engineering
of recombinant hypoallergenic allergen derivatives or the chemical
denaturation of recombinant allergens. For genetic engineering,
many different approaches, such as production of recombinant
allergen fragments, mutated allergens, and mosaic approaches,
have been used.51 These modifications aim to reduce IgE reactivity
and retain T-cell epitopes. The first immunotherapy trial with
recombinant allergen derivatives has been carried out with
recombinant fragments of rBet v 1 and a rBet v 1 trimer.13 The
outcome was that this treatment showed efficacy, induced
allergen-specific blocking IgG antibodies, reduced boosts of IgE
production caused by seasonal allergen exposure, and eliminated
IgE-mediated immediate side effects. Furthermore, because of
the hypoallergenic nature of the vaccine, higher doses were toler-
ated by the patients. However, it was noted that hypoallergenic
allergen derivatives induced systemic late-phase side effects in a
considerable number of patients.52A detailed analysis of the poten-
tialmechanismunderlying the late-phase side effects of the rBet v 1
fragments was then performed by using atopy patch testing, and it
seems that the late-phase side effects are IgE independent and
mediated by T cells.53 A recent atopy patch test study that used
hypoallergenic rBet v 1 fragments in patients with birch
pollen–induced rhinoconjunctivitis revealed that late-phase,
T cell–mediated side effects are quite common in birch pollen–
sensitized patients.54 In agreement with this result is the finding
that subcutaneous AIT with Bet v 1–derived long T-cell epitope–
containing peptides (AllerT; Anergis, Epalinges, Switzerland), a
treatment that is very similar to the first AIT with rBet v 1
fragments, frequently caused late-phase systemic side effects.55
FIG 3. Schematic representation of the development of BM32, a recombi-
nant B-cell epitope–based grass pollen allergy vaccine.
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late-phase reactions were observed when 75 injections were
given.55 It was also noticed that treatment with the hypoallergenic
Bet v 1 peptides induced considerable (ie, 3-fold) increases of Bet v
1–specific IgE antibodies.55 AITwith chemically denatured rBet v
1 was effective,56 but it seems that the chemical denaturation of the
recombinant allergen represented a difficult production step for the
development of a pharmaceutically acceptable vaccine. In fact,
chemical denaturation of allergen extracts and allergens yields
high-molecular-weight aggregates, which cannot be easily
manufactured in a reproducible manner, and the extent of the
reduction of IgE reactivity can vary.22
Recombinant hypoallergenic allergen derivatives of the major
cat allergen Fel d 1 have been successfully used for intralymphatic
AIT,57,58 and there are currently 2 clinical studies ongoing in
which a recombinant hypoallergenic mutant of carp parvalbumin,
mCyp c 1,59,60 is used for subcutaneous AIT of fish allergy.61
The currently available data from clinical studies with
recombinant or synthetic hypoallergenic allergen derivatives
containing allergen-specific T-cell epitopes thus indicate that
these derivatives induce blocking IgG antibodies and allow
injection of higher doses compared with wild-type allergens.
Treatment with recombinant hypoallergens is clinically effective,
and the risk of immediate allergic side effects can be reduced or
eliminated.13 It also seems that hypoallergens can be produced for
respiratory and food allergens and that this approach might be
generally applicable. However, disadvantages of T-cell
epitope–containing hypoallergens are that they can induce
T cell–mediated late-phase side effects, and therefore updosing
schedules are still needed. Furthermore, hypoallergens induce
increases in allergen-specific IgE production, and therefore they
might not be useful for preventive vaccination because they can
induce allergic sensitizations or boost subclinical IgE
sensitizations to become symptomatic. It is also not clear whether
it is possible to produce sufficiently immunogenic and nonaller-
genic derivatives by using recombinant technologies or synthetic
peptide chemistry for all allergen sources. For example, it was
very difficult to obtain recombinant hypoallergenic allergen
derivatives comprising the 4 major timothy grass pollen
allergens,62 and we are aware of only one report describing an
IgG-inducing hypoallergenic derivative of the major house dust
mite allergen Der p 1.63
Another approach for reducing the allergenic activity of AIT is
the use of synthetic T-cell epitope–containing peptides derived
from major allergens with the aim to induce T-cell tolerance.
Results of clinical trials performed with T-cell epitope peptides of
the major cat allergen Fel d 1 indicate that the treatment
might be clinically effective and that treatment effects can be
long-lasting.64-66 Furthermore, this treatment requires only a few
injections, and it seems that it has been possible to overcome the
originally observed late-phase T cell–mediated side effects.23
However, it is presently unclear what the immunologic
mechanism of this treatment is because no induction of
allergen-specific blocking IgG has been observed because the
peptides are too short to induce IgG responses. Another challenge
is that AIT with T-cell epitopes requires a large number of
peptides to address MHC diversity in patients, particularly
when several important allergens need to be covered by this
approach. Furthermore, not all of the peptides are easy to
manufacture and might present problems regarding solubility
and aggregation. Because T-cell epitope–containing peptides donot induce IgE sensitizations, they might well be suited for
preventive treatment.42B-CELL EPITOPE–BASED ALLERGY VACCINES:
A NEW KID ON THE BLOCK
B-cell epitope–based allergy vaccines contain intrinsically
non–IgE-reactive peptides of a length of approximately 20 to
40 amino acids, which are derived from the IgE-binding sites of
the major allergens of a given allergen source.37,67-69 To render
these peptides immunogenic so that they induce a robust IgG anti-
body response, which blocks IgE binding to the corresponding
allergen, the peptides need to be covalently linked to a protein car-
rier that is not related to the allergens and provides carrier-specific
T-cell help (Figs 2 and 3). The first proof-of-principle studies
showing that it is possible to use carrier-bound allergen peptides
to induce allergen-specific IgG antibodies were made with
allergen peptides from the major timothy grass pollen allergen
Phl p 1 and from the major birch pollen allergen Bet v 1, which
were chemically coupled to keyhole limpet hemocyanin.68,69 It
was found that these conjugates showed an even greater
reduction of allergenic activity compared with recombinant hypo-
allergens. Because of the fact that non–IgE-reactive peptides were
selected from the IgE-binding sites, it was possible to eliminate
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epitope–based allergy vaccines were found to exhibit a strongly
reduced potential to activate allergen-specific T cells and to
induce proinflammatory cytokine production in PBMCs from
allergic patients.70 In a skin test study performed in patients
with grass pollen allergy at the height of the grass pollen season,
it was found that the B-cell epitope–based grass pollen allergy
vaccine BM32 did not induce relevant IgE-mediated
immediate-type skin reactions, and the reduction of allergen-
specific T-cell epitopes in the vaccine rendered the vaccine
negative in atopy patch testing.71 These results indicated that
B-cell epitope–based allergy vaccines might have a reduced
capacity to induce late-phase, T cell–mediated side effects, which
was confirmed subsequently in clinical AIT studies
(ClinicalTrials.gov nos. NCT01445002 and NCT01538979).
Thus B-cell epitope–based vaccines appear to be more safe than
vaccines based on recombinant or synthetic allergy vaccines,
which contain allergen-specific T-cell epitopes. Chemical
coupling to keyhole limpet hemocyanin or viral particles was
left68,72,73 and vaccines were produced as recombinant fusion
proteins in Escherichia coli to yield defined products that are
easy to manufacture in a reproducible and pharmaceutical grade.
As carrier proteins, the viral proteins VP1 from human
rhinovirus74 and PreS from hepatitis B75 were used, and it was
found that the fusion proteins not only induced allergen-specific
IgG responses on immunization but also virus-specific antibodies,
which even had virus-neutralizing activities.76 Thus it is quite
possible that B-cell epitope–based allergy vaccines based on viral
carrier proteins might offer an antiviral effect in addition to the
AIT effect.
An important feature of the B-cell epitope–based vaccines is
that the use of a strongly immunogenic carrier allows induction of
allergen-specific IgG antibodies also against allergens that
intrinsically are poorly immunogenic and thus would induce a
poor blocking IgG response when used as wild-type allergen.
Furthermore, the selective inclusion of peptides from the
IgE-binding sites allows us to better focus allergen-specific IgG
responses toward the IgE-binding sites of allergens, which might
result in better protection.77 Because B-cell epitope–based allergy
vaccines show a strongly reduced allergenic activity, it is possible
to inject high doses into patients. Together with the good
immunogenicity of these vaccines, this indicates that only few
(ie, approximately 3) injections per year will be needed for
treatment and that the vaccines would thus be extremely
convenient for the patient.
The concept of using the hepatitis B–derived capsid protein
PreS as a carrier for B-cell epitope–based vaccines has been found
to be applicable to different allergens,70,75,77,78 and thus it appears
that it will be possible to use the PreS-based technology for
construction of vaccines for allergens from different sources,
such as inhalant, food, and venom allergens. The analysis of
serum samples from patients who have been treated with
BM32, a grass pollen vaccine based on the B-cell epitope concept,
has shown that the vaccine induces a highly selective allergen-
specific IgG response (ie, IgG15 IgG4 > IgG2) but does not boost
allergen-specific IgE responses. Thus it is quite possible that
B-cell epitope–based allergy vaccines can be used for preventive
vaccination because they seem to have no IgE-sensitizing
potential. Although the clinical relevance of AIT-induced IgE
sensitizations has not been demonstrated, they might become a
potential bottleneck for the application of AIT in a preventivesetting. In fact, we found that AIT with BM32, even when
adsorbed to the TH2-driving adjuvant aluminum hydroxide, did
not boost allergen-specific IgE responses. Indeed, experiments
performed in mice indicate that immunization with B-cell
epitope–based allergy vaccines might be useful to prevent allergic
sensitization.79
According to currently available in vitro, animal, and in vivo
data from clinical studies, B-cell epitope–based vaccines have
several modes of action. The vaccines induce allergen-specific
IgG antibodies that inhibit allergen-induced cross-linking of
IgE on mast cells and basophils and thus immediate allergic
inflammation. Furthermore, the IgG antibodies inhibit
IgE-facilitated allergen presentation and thus will likely suppress
also T cell–mediated allergic inflammation. Finally, it seems that
vaccine-induced IgG antibodies also reduce the boosts of IgE
production induced by allergen exposure, and thus treatment
might have a long-lasting effect because of a reduction in
allergen-specific IgE levels.
In summary, recombinant B-cell epitope allergy vaccines are
the new kid on the block and hold great promise to profoundly
improve AIT and become applicable also for preventive allergy
vaccination.REFERENCES
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